Radium-223 for patients with castration resistant prostate cancer with bone metastases a review of clinical effectiveness, cost-effectiveness and guidelines

The aim of this report is to review the clinical effectiveness, cost-effectiveness, and evidence-based guidelines of radium-223 (Ra-223) in patients with bone metastatic castration-resistant prostate cancer (mCRPC)

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2016, 31 October 2016
Series:Rapid response report: summary with critical appraisal
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The aim of this report is to review the clinical effectiveness, cost-effectiveness, and evidence-based guidelines of radium-223 (Ra-223) in patients with bone metastatic castration-resistant prostate cancer (mCRPC)
Item Description:"CADTH Rapid Response Service."
Physical Description:1 PDF file (29 pages) illustrations